Quotes 5-day view Delayed Nasdaq
179 628 Volume
Estimated financial data (e) (USD)
Net income 2022
Net Debt 2022
P/E ratio 2022
Net income 2023
Net Debt 2023
P/E ratio 2023
Capi. / Sales 2022
Capi. / Sales 2023
Nbr of Employees
Baudax Bio, Inc. is a pharmaceutical company. The Company is primarily focused on commercializing and developing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. This injectable form of IV meloxicam, utilizes NanoCrystal...
All news about BAUDAX BIO, INC.
02/01 Certain common stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1..
02/01 Certain warrants of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB..
02/01 Certain restricted stock units of Baudax Bio, Inc. are subject to a Lock-Up Agreement E..
02/01 Certain options of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-..
01/24 Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
01/24 Top Midday Gainers
01/24 Baudax Bio Reports Positive Outcome of Initial Analysis in Phase 2 Trial of BX1000; Sha..
01/24 Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial ..
01/24 Baudax Bio, Inc. Announces Positive Outcome of Interim Analysis of Phase Ii Randomized ..
01/09 Baudax Bio : Corporate Overview
01/09 Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
01/04 North American Morning Briefing: Futures Rise -2-
01/03 Noble Capital Downgrades Baudax Bio to Market Perform Rating From Outperform
2022 Baudax Bio, Inc. : Other Events (form 8-K)
2022 Top Premarket Gainers
News in other languages on BAUDAX BIO, INC.
Analyst Recommendations on BAUDAX BIO, INC.
Technical analysis trends BAUDAX BIO, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target